Gastroenterology: NTC submits marketing authorisation application for KLEERKOL® in EU

  • Apr 19, 2022

NTC announces the submission of the marketing authorisation application through the European Decentralised Procedure (DCP) for its development product NTC015 (Kleerkol®) for bowel preparation for colonoscopy

NTC grants Théa the marketing rights in Western Europe for its innovative preservative-free lubricating and lenitive eye spray

  • Feb 02, 2022

NTC Srl, an R&D focused pharmaceutical company headquartered in Italy, with distribution partners in over 100 countries, announced today that it has entered into an exclusive agreement with Théa for NTC026

NTC and I-MED Pharma form strategic partnership to bring the leading HA-based dry eye ointment to the United States market

  • Dec 15, 2021

NTC Srl and I-MED Pharma Inc announced today that I-DEFENSE®, a long-lasting, lubricating ointment containing 0.4% sodium hyaluronate indicated for the relief of dry eyes and lagophthalmos symptoms has been successfully registered with the U.S.A. Food and Drug Administration. It is the first European NTC medical device product for ophthalmic use approved in the U.S.A.